International experience of using olaparib for metastatic castration-resistant prostate cancer: literature review

被引：0
|
作者：
Matveev, V. B. [1 ]
Khalmurzaev, O. A. [1 ]
Evsyukova, O., I [1 ]
机构：
[1] Minist Hlth Russia, NN Blokhin Natl Med Res Ctr Oncol, 24 Kashirskoe Shosse, Moscow 115478, Russia
来源：
ONKOUROLOGIYA | 2020年 / 16卷 / 04期
关键词：
prostate cancer; HRR mutations; BRCA; olaparib; DNA-REPAIR;
D O I：
10.17650/1726-9776-2020-16-4-197-206
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The following review presents a problem of metastatic castration-resistant prostate cancer and its association with germline or somatic mutations in homologous recombination repair (HRR). In 2020, olaparib was approved in the Russian Federation as a monotherapy for metastatic castration-resistant prostate cancer with germline or somatic mutations of genes involved in DNA repair by homologous recombination, after progression on therapy with new hormonal drugs. We describe a review of the main olaparib clinical trials assessing its efficacy, safety and tolerance in metastatic castration-resistant prostate cancer patients.
引用
收藏
页码：197 / 206
页数：10
相关论文
共 50 条
  • [21] Monitoring of treatment for metastatic castration-resistant prostate cancer
    Hinz, Stefan
    AKTUELLE UROLOGIE, 2017, 48 (03) : 225 - 229
  • [22] Targeting NPRL2 to enhance the efficacy of Olaparib in castration-resistant prostate cancer
    Chen, Xin
    Chen, Zhixiong
    Zheng, Bin
    Tang, Wei
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2019, 508 (02) : 620 - 625
  • [23] New drugs in metastatic castration-resistant prostate cancer
    Albiges, L.
    Loriot, Y.
    Gross-Goupil, M.
    Rouge, T. de La Motte
    Blesius, A.
    Escudier, B.
    Massard, C.
    Fizazi, K.
    BULLETIN DU CANCER, 2010, 97 (01) : 149 - 159
  • [24] Perspectives on Treatment of Metastatic Castration-Resistant Prostate Cancer
    Merseburger, Axel S.
    Bellmunt, Joaquim
    Jenkins, Cheryl
    Parker, Chris
    Fitzpatrick, John M.
    ONCOLOGIST, 2013, 18 (05) : 558 - 567
  • [25] Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer
    Chen, Xiangyu
    Pan, Yang
    Wang, Qihua
    Ren, Congzhe
    Li, Muwei
    Hao, Xuexue
    Xie, Lijun
    Liu, Xiaoqiang
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [26] Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer
    Su, Dan
    Wu, Bin
    Shi, Lizheng
    FRONTIERS IN PHARMACOLOGY, 2021, 11
  • [27] Advancing therapies in metastatic castration-resistant prostate cancer
    Baciarello, Giulia
    Gizzi, Marco
    Fizazi, Karim
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (16) : 1797 - 1804
  • [28] The changing landscape in metastatic castration-resistant prostate cancer
    Leibowitz-Amit, Raya
    Joshua, Anthony M.
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2013, 7 (03) : 243 - 248
  • [29] Talazoparib for the Treatment of Metastatic Castration-resistant Prostate Cancer
    Qureshi, Zaheer
    Fatima, Eeshal
    Safi, Adnan
    Khanzada, Mikail
    Altaf, Faryal
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2025, 48 (04): : 206 - 214
  • [30] Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
    Warli, Syah Mirsya
    Velaro, Adrian Joshua
    Firsty, Naufal Nandita
    Tala, Zaimah Zulkarnaini
    WORLD JOURNAL OF ONCOLOGY, 2023, 14 (06) : 518 - 528
12345